Tianjin Ringpu Bio-Technology Co.,Ltd. (SHE:300119)
18.30
-0.34 (-1.82%)
Apr 9, 2026, 2:30 PM CST
SHE:300119 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 651.19 | 487.37 | 338.84 | 384.42 | 1,310 |
Short-Term Investments | - | - | 199.13 | 16.01 | 121.01 |
Trading Asset Securities | 1,043 | 1,451 | 1,283 | 1,501 | 577.88 |
Cash & Short-Term Investments | 1,694 | 1,939 | 1,821 | 1,901 | 2,009 |
Cash Growth | -12.62% | 6.44% | -4.20% | -5.36% | 189.36% |
Accounts Receivable | 1,018 | 1,078 | 1,004 | 756.21 | 606.61 |
Other Receivables | 72.56 | 60.18 | 84.04 | 36.24 | 44.45 |
Receivables | 1,090 | 1,138 | 1,088 | 792.45 | 651.06 |
Inventory | 502.12 | 499.57 | 496.79 | 367.06 | 360.47 |
Prepaid Expenses | - | 0.7 | 5.08 | - | - |
Other Current Assets | 88.19 | 72.15 | 80 | 32.51 | 41.15 |
Total Current Assets | 3,375 | 3,649 | 3,491 | 3,093 | 3,062 |
Property, Plant & Equipment | 1,659 | 1,926 | 1,663 | 1,600 | 1,300 |
Long-Term Investments | 1,348 | 1,169 | 1,076 | 879.55 | 751.3 |
Goodwill | 442.99 | 442.26 | 229.43 | 67.8 | 67.8 |
Other Intangible Assets | 484.05 | 493.14 | 238.49 | 258.54 | 245.67 |
Long-Term Accounts Receivable | - | 1.46 | 3.09 | - | - |
Long-Term Deferred Tax Assets | 36.95 | 26.95 | 12.37 | 10.06 | 50.08 |
Long-Term Deferred Charges | 198.44 | 193.94 | 185.37 | 143.58 | 140.58 |
Other Long-Term Assets | 111.62 | 64.21 | 105.85 | 53.09 | 73.97 |
Total Assets | 7,656 | 7,966 | 7,006 | 6,106 | 5,691 |
Accounts Payable | 436.83 | 550.24 | 599.36 | 397.43 | 281.45 |
Accrued Expenses | 82.37 | 85.04 | 89.89 | 85.18 | 78.88 |
Short-Term Debt | 785.59 | 800.78 | 550.77 | 666.71 | 591.11 |
Current Portion of Long-Term Debt | - | 50.5 | 14.35 | 9 | - |
Current Portion of Leases | - | 10.58 | 10.38 | 9.82 | 47.15 |
Current Income Taxes Payable | - | 10.97 | 16.43 | 20.6 | 6.99 |
Current Unearned Revenue | 72.76 | 56.43 | 23.6 | 22.36 | 34.02 |
Other Current Liabilities | 512.06 | 686.3 | 265.09 | 98.69 | 84.18 |
Total Current Liabilities | 1,890 | 2,251 | 1,570 | 1,310 | 1,124 |
Long-Term Debt | 368.42 | 513.81 | 307.11 | 191.18 | 90.13 |
Long-Term Leases | 2.58 | 5.25 | 14.41 | 0.97 | 10.6 |
Long-Term Unearned Revenue | 92.66 | 63.13 | 53.54 | 50.8 | 53.64 |
Long-Term Deferred Tax Liabilities | 118.02 | 125.81 | 76.63 | 52.44 | 88.99 |
Total Liabilities | 2,471 | 2,959 | 2,022 | 1,605 | 1,367 |
Common Stock | 464.75 | 465.85 | 466.28 | 468.02 | 468.34 |
Additional Paid-In Capital | 2,145 | 2,157 | 2,265 | 2,203 | 2,223 |
Retained Earnings | 2,285 | 2,019 | 1,903 | 1,592 | 1,409 |
Treasury Stock | -191.21 | -171.88 | -69.08 | -41.15 | -67.07 |
Comprehensive Income & Other | 0.05 | - | - | - | - |
Total Common Equity | 4,703 | 4,470 | 4,566 | 4,222 | 4,033 |
Minority Interest | 481.54 | 536.97 | 418.4 | 279.59 | 290.99 |
Shareholders' Equity | 5,185 | 5,007 | 4,984 | 4,501 | 4,324 |
Total Liabilities & Equity | 7,656 | 7,966 | 7,006 | 6,106 | 5,691 |
Total Debt | 1,157 | 1,381 | 897.03 | 877.68 | 738.99 |
Net Cash (Debt) | 537.29 | 557.7 | 924.34 | 1,024 | 1,270 |
Net Cash Growth | -3.66% | -39.66% | -9.70% | -19.40% | 816.50% |
Net Cash Per Share | 1.18 | 1.21 | 1.99 | 2.21 | 3.16 |
Filing Date Shares Outstanding | 453.99 | 455.75 | 462.59 | 463.89 | 464.21 |
Total Common Shares Outstanding | 453.99 | 455.75 | 462.59 | 463.89 | 464.21 |
Working Capital | 1,485 | 1,398 | 1,921 | 1,784 | 1,938 |
Book Value Per Share | 10.36 | 9.81 | 9.87 | 9.10 | 8.69 |
Tangible Book Value | 3,776 | 3,535 | 4,098 | 3,895 | 3,719 |
Tangible Book Value Per Share | 8.32 | 7.76 | 8.86 | 8.40 | 8.01 |
Buildings | - | 1,599 | 1,318 | 1,041 | 836.41 |
Machinery | - | 1,017 | 765.81 | 626.75 | 337.07 |
Construction In Progress | - | 62.69 | 87.83 | 373.75 | 379.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.